Overview

A Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg as a Treatment for Acute Pain and the Prevention of OINV

Status:
Completed

Trial end date:
2018-11-30

Target enrollment:

Participant gender:

Summary

To determine the analgesic efficacy of CL-108 5 mg by comparison with placebo and the anti-emetic efficacy of CL-108 5 mg by comparison with hydrocodone 5 mg/acetaminophen 325 mg.

Phase:

Phase 3

Details

Lead Sponsor:

Charleston Laboratories, Inc

Treatments:

Diphenhydramine
Hydrocodone
Promethazine